Background autoimmune adrenalitis and direct infiltration by neoplastic lymphoid cells are postulated to be the most common mechanisms of adrenal hypofunction observed in PAL patients. Considering that >90% of the adrenal gland needs to be destroyed before adrenal pathology becomes clinically apparent, increasing numbers of PAL patients are currently being diagnosed with preserved adrenal function (1) . This, in combination with nonspecific clinical features and imaging characteristics, makes early diagnosis more challenging.
Diffuse large B-cell NHL (DLBCL) is the most common type of PAL reported till date, with only 5 of the non-B , not documented; ±, Ann Arbor staging system; $ , modified Luano staging system similar to that used for gastrointestinal lymphoma; £ , modified International Prognostic Index scoring system; €, DLBCL-diffuse large B cell non-Hodgkin lymphoma PBL: plasmablastic lymphoma, which was reported in a non-HIV patient; NKTCL: extranodal natural killer/T cell non-Hodgkin lymphoma; EBV: Epstein-Barr virus; ≠ , CT, rituximabbased combined systemic chemotherapy; RT: postoperative radiotherapy to the adrenal bed; surgery, adrenalectomy Table 1 . Primary adrenal non-Hodgkin lymphoma (PAL): brief review of literature from selected series of patients cell phenotype (1 CD30 positive anaplastic large cell lymphoma and 3 T cell, 1 NK/T cell lymphoma of nasal type). Recent studies on primary adrenal DLBCL showed predominance of a nongerminal center B cell phenotype with increased expression of BCL-6 and MUM-1, which together confer poor prognosis in these patients (4, 5) .
Previous studies reported unfavorable outcomes of primary adrenal DLBCL; presently, no consensus exists for optimal management (5-7). Mojos et al. reported unfavorable outcomes among 10 PAL patients with BCL-6 gene rearrangements, despite preserved adrenal function (1/10 adrenal insufficiency) (4).Wang et al, in a review of 55 patients, found no correlation between adrenal hypofunction (20/40 tested) and tumor size (6) . However, a recent study reported favorable therapeutic outcomes among 31 patients (6/16 with adrenal insufficiency) following rituximab-based chemotherapy when applying modified Lugano staging (similar to that used for gastrointestinal lymphoma) and modified International Prognostic Scoring (IPS) system (7). Bilateral adrenal involvement was considered as stage I (single site/extranodal) rather than Ann Arbor stage IV. The modified low/intermediate IPS category showed longer overall survival than the high-risk category, although progression-free survival did not differ between groups. Thus, a high index of suspicion, early diagnosis, and prompt therapy with a modified approach may offer some hope for these patients.
